|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERTAD1 |
Gene summary for SERTAD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERTAD1 | Gene ID | 29950 |
| Gene name | SERTA domain containing 1 | |
| Gene Alias | SEI1 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | Q53GC0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29950 | SERTAD1 | CA_HPV_1 | Human | Cervix | CC | 3.22e-03 | -1.69e-01 | 0.0264 |
| 29950 | SERTAD1 | CCI_3 | Human | Cervix | CC | 3.11e-03 | -3.89e-01 | 0.516 |
| 29950 | SERTAD1 | CCII_1 | Human | Cervix | CC | 6.83e-06 | -3.93e-01 | 0.3249 |
| 29950 | SERTAD1 | T1 | Human | Cervix | CC | 2.88e-06 | 4.63e-01 | 0.0918 |
| 29950 | SERTAD1 | LZE4T | Human | Esophagus | ESCC | 3.14e-19 | 1.30e+00 | 0.0811 |
| 29950 | SERTAD1 | LZE8T | Human | Esophagus | ESCC | 8.19e-21 | 1.43e+00 | 0.067 |
| 29950 | SERTAD1 | LZE20T | Human | Esophagus | ESCC | 2.31e-07 | 9.93e-01 | 0.0662 |
| 29950 | SERTAD1 | LZE22T | Human | Esophagus | ESCC | 1.46e-04 | 1.59e+00 | 0.068 |
| 29950 | SERTAD1 | LZE24T | Human | Esophagus | ESCC | 8.73e-21 | 1.49e+00 | 0.0596 |
| 29950 | SERTAD1 | LZE21T | Human | Esophagus | ESCC | 3.19e-03 | 9.19e-01 | 0.0655 |
| 29950 | SERTAD1 | LZE6T | Human | Esophagus | ESCC | 2.08e-02 | 8.81e-01 | 0.0845 |
| 29950 | SERTAD1 | P1T-E | Human | Esophagus | ESCC | 9.18e-26 | 2.69e+00 | 0.0875 |
| 29950 | SERTAD1 | P2T-E | Human | Esophagus | ESCC | 1.68e-38 | 1.12e+00 | 0.1177 |
| 29950 | SERTAD1 | P4T-E | Human | Esophagus | ESCC | 2.26e-31 | 1.31e+00 | 0.1323 |
| 29950 | SERTAD1 | P5T-E | Human | Esophagus | ESCC | 2.03e-47 | 1.53e+00 | 0.1327 |
| 29950 | SERTAD1 | P8T-E | Human | Esophagus | ESCC | 1.64e-56 | 2.14e+00 | 0.0889 |
| 29950 | SERTAD1 | P9T-E | Human | Esophagus | ESCC | 6.07e-13 | 9.34e-01 | 0.1131 |
| 29950 | SERTAD1 | P10T-E | Human | Esophagus | ESCC | 8.72e-33 | 1.62e+00 | 0.116 |
| 29950 | SERTAD1 | P11T-E | Human | Esophagus | ESCC | 3.00e-34 | 3.10e+00 | 0.1426 |
| 29950 | SERTAD1 | P12T-E | Human | Esophagus | ESCC | 1.14e-49 | 2.02e+00 | 0.1122 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
| GO:00063684 | Cervix | CC | transcription elongation from RNA polymerase II promoter | 17/2311 | 69/18723 | 3.65e-03 | 2.33e-02 | 17 |
| GO:00063545 | Cervix | CC | DNA-templated transcription, elongation | 20/2311 | 91/18723 | 6.88e-03 | 3.74e-02 | 20 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
| GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
| GO:00480962 | Esophagus | ESCC | chromatin-mediated maintenance of transcription | 11/8552 | 11/18723 | 1.80e-04 | 1.16e-03 | 11 |
| GO:0045815 | Esophagus | ESCC | positive regulation of gene expression, epigenetic | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
| GO:00063544 | Liver | Cirrhotic | DNA-templated transcription, elongation | 35/4634 | 91/18723 | 2.56e-03 | 1.53e-02 | 35 |
| GO:00063683 | Liver | Cirrhotic | transcription elongation from RNA polymerase II promoter | 28/4634 | 69/18723 | 2.70e-03 | 1.58e-02 | 28 |
| GO:007190011 | Liver | Cirrhotic | regulation of protein serine/threonine kinase activity | 110/4634 | 359/18723 | 6.19e-03 | 3.08e-02 | 110 |
| GO:000635411 | Liver | HCC | DNA-templated transcription, elongation | 64/7958 | 91/18723 | 7.00e-08 | 1.44e-06 | 64 |
| GO:000636811 | Liver | HCC | transcription elongation from RNA polymerase II promoter | 50/7958 | 69/18723 | 4.32e-07 | 7.22e-06 | 50 |
| GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
| GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
| GO:0000079 | Liver | HCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 55/7958 | 94/18723 | 1.25e-03 | 6.91e-03 | 55 |
| GO:1904029 | Liver | HCC | regulation of cyclin-dependent protein kinase activity | 57/7958 | 98/18723 | 1.26e-03 | 6.92e-03 | 57 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERTAD1 | SNV | Missense_Mutation | c.572N>T | p.Ser191Phe | p.S191F | Q9UHV2 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SERTAD1 | SNV | Missense_Mutation | rs768979696 | c.226N>T | p.Arg76Cys | p.R76C | Q9UHV2 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SERTAD1 | SNV | Missense_Mutation | c.550N>C | p.Asn184His | p.N184H | Q9UHV2 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERTAD1 | SNV | Missense_Mutation | rs200028938 | c.640N>A | p.Glu214Lys | p.E214K | Q9UHV2 | protein_coding | deleterious(0.01) | benign(0.147) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SERTAD1 | SNV | Missense_Mutation | novel | c.665N>C | p.Leu222Pro | p.L222P | Q9UHV2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SERTAD1 | SNV | Missense_Mutation | c.53N>A | p.Pro18His | p.P18H | Q9UHV2 | protein_coding | tolerated(0.1) | benign(0.037) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERTAD1 | SNV | Missense_Mutation | novel | c.194G>A | p.Arg65Gln | p.R65Q | Q9UHV2 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SERTAD1 | SNV | Missense_Mutation | c.629T>C | p.Leu210Pro | p.L210P | Q9UHV2 | protein_coding | tolerated(0.07) | probably_damaging(0.98) | TCGA-BS-A0TD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERTAD1 | SNV | Missense_Mutation | c.481N>T | p.Ala161Ser | p.A161S | Q9UHV2 | protein_coding | tolerated(0.4) | possibly_damaging(0.868) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERTAD1 | SNV | Missense_Mutation | rs768979696 | c.226N>T | p.Arg76Cys | p.R76C | Q9UHV2 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |